Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glutamine PET Imaging in LAM
NCT04388371Phase 1Completed
- Sponsor
- Vanderbilt University Medical Center
- Start
- Oct 2019
- Primary completion
- Jun 2021
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label trial of L-[5-11C]-glutamine in lymphangioleiomyomatosis (LAM) (2 arms), sponsored by Vanderbilt University Medical Center. Primary endpoint: Uptake of the PET tracer throughout the entire lung and any associated neoplasms at 8 weeks. Started Oct 2019; status: completed.
02
Drugs
L-[5-11C]-glutamine
03
Conditions
lymphangioleiomyomatosis (LAM)
Beyond the preview
Go deeper on NCT04388371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04388371.